# OnCo record paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012" ;
  schema:name "COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis"@en ;
  schema:description "Ruxolitinib shrank the enlarged spleen by more than a third in 42% of myelofibrosis patients versus under 1% on placebo, and halved symptom scores in nearly half."@en ;
  schema:url <https://onco.cc/key-papers/paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1110557>, <https://clinicaltrials.gov/study/NCT00952289> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1110557> ;
  schema:datePublished "2012"^^xsd:gYear ;
  schema:author "Verstovsek S, Mesa RA, Gotlib J, et al." ;
  onco:related <https://onco.cc/key-papers/paper-momentum-momelotinib-lancet-2023/> ;
  onco:cancers <https://onco.cc/cancers/myeloproliferative-neoplasms/> ;
  onco:targets <https://onco.cc/targets/jak2/> ;
  onco:drugs <https://onco.cc/drugs/ruxolitinib/>, <https://onco.cc/drugs/fedratinib/>, <https://onco.cc/drugs/pacritinib/>, <https://onco.cc/drugs/momelotinib/> ;
  onco:companies <https://onco.cc/companies/incyte/>, <https://onco.cc/companies/novartis/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-rare-cancers/> ;
  onco:journals <https://onco.cc/journals/nejm/> .